Klobučar, I., Degoricija, V., Potočnjak, I., Trbušić, M., Pregartner, G., Berghold, A. ... Frank, S. (2022). HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients. Biomedicines, 10. (7). doi: 10.3390/biomedicines10071668
Klobučar, Iva, et al. "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients." Biomedicines, vol. 10, no. 7, 2022. https://doi.org/10.3390/biomedicines10071668
Klobučar, Iva, Vesna Degoricija, Ines Potočnjak, Matias Trbušić, Gudrun Pregartner, Andrea Berghold, Eva Fritz Petrin, Hansjörg Habisch, Tobias Madl and Saša Frank. "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients." Biomedicines 10, no. 7 (2022). https://doi.org/10.3390/biomedicines10071668
Klobučar, I., et al. (2022) 'HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients', Biomedicines, 10(7). doi: 10.3390/biomedicines10071668
Klobučar I, Degoricija V, Potočnjak I, Trbušić M, Pregartner G, Berghold A, and sur.. HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients. Biomedicines [Internet]. 2022 July 11 [cited 2024 November 26];10(7). doi: 10.3390/biomedicines10071668
I. Klobučar, et al., "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients", Biomedicines, vol. 10, no. 7, July 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:642691. [Accessed: 26 November 2024]